These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4193976)

  • 21. New approaches to treatment of osteogenesis imperfecta.
    Castells S
    Clin Orthop Relat Res; 1973 Jun; (93):239-49. PubMed ID: 4353023
    [No Abstract]   [Full Text] [Related]  

  • 22. Osteogenesis imperfecta and intravenous pamidronate.
    Banerjee I; Shortland GJ; Evans WD; Gregory JW
    Arch Dis Child; 2002 Dec; 87(6):562-3. PubMed ID: 12456578
    [No Abstract]   [Full Text] [Related]  

  • 23. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
    Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
    Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E; Magnusson P; Eksborg S; Söderhäll S
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteogenesis imperfecta tarda treated with sodium fluoride.
    Kuzemko JA
    Arch Dis Child; 1970 Aug; 45(242):581-2. PubMed ID: 5506948
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased inorganic serum pyrophosphate in serum and urine of patients with osteogenesis imperfecta.
    Armstrong D; VanWormer D; Solomons CC
    Clin Chem; 1975 Jan; 21(1):104-8. PubMed ID: 163711
    [No Abstract]   [Full Text] [Related]  

  • 28. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.
    Sakkers R; Kok D; Engelbert R; van Dongen A; Jansen M; Pruijs H; Verbout A; Schweitzer D; Uiterwaal C
    Lancet; 2004 May; 363(9419):1427-31. PubMed ID: 15121405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Peri-osteocytic calcium fixation under calcitonin treatment. Microradiographic study using automatic analysis of images in 8 cases of osteogenesis imperfecta].
    Duriez J; Flautre B
    Nouv Presse Med; 1975 Jan; 04(2):97-100. PubMed ID: 1138231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of porcine calcitonin in osteogenesis imperfecta in Thai children: a preliminary report.
    Tuchinda C; Punnakanta L; Angsusingha K; Soebsanguan K
    J Med Assoc Thai; 1977 Jan; 60(1):26-9. PubMed ID: 557524
    [No Abstract]   [Full Text] [Related]  

  • 31. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series.
    Schwartz S; Joseph C; Iera D; Vu DD
    J Can Dent Assoc; 2008; 74(6):537-42. PubMed ID: 18644240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of synthetic salmon calcitonin therapy in children with osteogenesis imperfecta.
    Rebelo I; da Silva LP; Blanco JC; Monteiro ME; Ferreira NC
    J Int Med Res; 1989; 17(4):401-5. PubMed ID: 2792559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
    Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
    J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
    Choi JH; Shin YL; Yoo HW
    J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
    Kanno J; Saito-Hakoda A; Kure S; Fujiwara I
    J Bone Miner Metab; 2018 May; 36(3):344-351. PubMed ID: 28528406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteogenesis Imperfecta: A Pediatric Orthopedic Perspective.
    Franzone JM; Shah SA; Wallace MJ; Kruse RW
    Orthop Clin North Am; 2019 Apr; 50(2):193-209. PubMed ID: 30850078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of osteogenesis imperfecta with (+)-catechin (author's transl)].
    Stöss H; Pesch HJ; Spranger J
    Dtsch Med Wochenschr; 1979 Dec; 104(50):1774, 1777-8. PubMed ID: 510214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.
    Bishop N; Harrison R; Ahmed F; Shaw N; Eastell R; Campbell M; Knowles E; Hill C; Hall C; Chapman S; Sprigg A; Rigby A
    J Bone Miner Res; 2010 Jan; 25(1):32-40. PubMed ID: 19580461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
    Aström E; Jorulf H; Söderhäll S
    Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.